In a report released today, Robert Burns from H.C. Wainwright upgraded BioNTech SE (BNTX) to Buy, with a price target of $69.00. The company’s shares closed last Monday at $60.17.
According to TipRanks.com, Burns is a 5-star analyst with an average return of 29.9% and a 82.8% success rate. Burns covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Black Diamond Therapeutics, and Springworks Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioNTech SE with a $55.33 average price target.
See today’s analyst top recommended stocks >>
Based on BioNTech SE’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $27.66 million and GAAP net loss of $53.39 million. In comparison, last year the company earned revenue of $26.15 million and had a GAAP net loss of $40.65 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioNTech SE focuses on the development of molecular immune therapies and biomarker-based diagnostic approaches. The firm develops and manufactures biomarker-based in vitro diagnostic devices (IVDD) and commercializes products. It offers drug discovery services for therapeutic areas including infectious diseases, allergies and autoimmune disorders. The company was founded by Christopher Huber, Özlem Türeci and Ugur Sahin in 2008 and is headquartered in Mainz, Germany.
Read More on BNTX:
